New hope for asian brain tumor patients: targeted drug slows cancer growth

NCT ID NCT06780930

Ongoing Disease control Sponsor: Servier Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 27 times

Summary

This study tests an experimental drug called vorasidenib in about 57 Asian patients with a slow-growing brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). Half the participants get the drug, half get a placebo, and researchers track how long it takes for the tumor to grow or for the patient to die. The goal is to see if the drug can delay disease progression and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Chang Gung Memorial Hospital,

Taoyuan, Taiwan
Huashan Hospital Fudan University

Shanghai, 200040, China
Sanbo Brain Hospital, Capital Medical University

Beijing, China
Taipei Veterans General Hospital

Taipei, Taiwan
The Second Affiliated Hospital of Air Force Military Medical University

Xi'an, China
The Second People's Hospital of Shenzhen

Shenzhen, Guangdong, China
Tiantan Hospital

Beijing, 100070, China
West China Hospital Sichuan University

Chengdu, Sichuan, China

Conditions

Explore the condition pages connected to this study.

RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA